JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Field-Medical-Inc-PFA

More Like This

PR Newswire associated0

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

PR Newswire associated0

Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025

PR Newswire associated0

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

PR Newswire associated0

FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT HEART RHYTHM 2025

PR Newswire associated0

Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

PR Newswire associated0

Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

PR Newswire associated0

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA

PR Newswire associated0

Field Medical, Inc. Announces Oversubscribed Seed Round to Advance Next-Generation Cardiac Ablation Technology